Human cytomegalovirus-viruria in hematopoietic stem cell transplant recipients: Context and impact - 05/05/23
Highlights |
• | Urinary CMV shedding occurs in some HSCT recipients. |
• | CMV-viruria is not directly related to the degree of immunosuppression. |
• | CMV-viruria primarily occurs in CMV-seropositive (R + ) HSCT recipients. |
• | CMV-viruria has no impact on mortality or renal function post-HSCT. |
Abstract |
Background |
Episodes of CMV-viruria have been reported in hematopoietic stem cell transplant (HSCT) recipients, but their context of occurrence, pathophysiology, and clinical significance remain misunderstood.
Methods |
Uurine samples from 517 recipients were collected. Clinical features of recipients with or without episodes of CMV-viruria were retrospectively compared.
Results |
CMV-viruria was detected in 15.5 % of cases. Age, sex, type of transplantation, HLA-matching, conditioning regimen, and immunosuppressive therapies did not differ between patients with and without CMV-viruria. CMV-seropositive status (R + ) was more frequent among CMV-viruric recipients. Cumulated mortality did not differ between the two groups but graft-versus-host diseases occurred more frequently among CMV-viruric patients (p = 0.04). No reduction of the estimated glomerular filtration rates was observed in CMV-viruric recipients.
Conclusions |
CMV-viruria primarily occurs in CMV-seropositive recipients and is not related to the degree of immunosuppression. We suggest that CMV-viruria is primarily related to the inability of the graft immune system to contain CMV-replication in R + patients. CMV-viruria is not associated with increased mortality or renal dysfunction.
Le texte complet de cet article est disponible en PDF.Keywords : Cytomegalovirus, Viruria, Hematopoietic Stem Cell Transplantation
Plan
Vol 53 - N° 3
Article 104651- avril 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?